Skip to main content

Advertisement

SpringerLink
Log in

Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS

  • Brief Review
  • Published:
Journal of Neuroimmune Pharmacology Aims and scope Submit manuscript

Abstract

Intranasal drug administration is a noninvasive method of bypassing the blood–brain barrier (BBB) to deliver neurotrophins and other therapeutic agents to the brain and spinal cord. This method allows drugs that do not cross the BBB to be delivered to the central nervous system (CNS) and eliminates the need for systemic delivery, thereby reducing unwanted systemic side effects. Delivery from the nose to the CNS occurs within minutes along both the olfactory and trigeminal neural pathways. Intranasal delivery occurs by an extracellular route and does not require that drugs bind to any receptor or undergo axonal transport. Intranasal delivery also targets the nasal associated lymphatic tissues (NALT) and deep cervical lymph nodes. In addition, intranasally administered therapeutics are observed at high levels in the blood vessel walls and perivascular spaces of the cerebrovasculature. Using this intranasal method in animal models, researchers have successfully reduced stroke damage, reversed Alzheimer’s neurodegeneration, reduced anxiety, improved memory, stimulated cerebral neurogenesis, and treated brain tumors. In humans, intranasal insulin has been shown to improve memory in normal adults and patients with Alzheimer’s disease. Intranasal delivery strategies that can be employed to treat and prevent NeuroAIDS include: (1) target antiretrovirals to reach HIV that harbors in the CNS; (2) target therapeutics to protect neurons in the CNS; (3) modulate the neuroimmune function of moncyte/macrophages by targeting the lymphatics, perivascular spaces of the cerebrovasculature, and the CNS; and (4) improve memory and cognitive function by targeting therapeutics to the CNS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alcalay RN, Giladi E, Pick CG, Gozes I (2004) Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361:128–131

    Article  PubMed  CAS  Google Scholar 

  • Banks WA, During MJ, Niehoff ML (2004) Brain uptake of the glucagon-like peptide-1 antagonist exendin(9–39) after intranasal administration. J Pharmacol Exp Ther 309:469–475

    Article  PubMed  CAS  Google Scholar 

  • Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29:1326–1334

    Article  PubMed  CAS  Google Scholar 

  • Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516

    Article  PubMed  CAS  Google Scholar 

  • Capsoni S, Giannotta S, Cattaneo A (2002) Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Nat Acad Sci USA 99:12432–12437

    Article  PubMed  CAS  Google Scholar 

  • Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey WH II (1998) Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimer’s Dis 1:35–44

    CAS  Google Scholar 

  • da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho Mda G, Gattass CR (2006) Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol 65 S1:2–1:9

    Google Scholar 

  • De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A (2005) Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 102:3811–3816

    Article  PubMed  CAS  Google Scholar 

  • Dhanda DS, Frey WH 2nd, Leopold D, Kompella UB (2005) Approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol 5:64–72

    CAS  Google Scholar 

  • Dou H, Kingsley JD, Mosley RL, Gelbard HA, Gendelman HE (2004) Neuroprotective strategies for HIV-1 associated dementia. Neurotox Res 6:503–521

    Article  PubMed  Google Scholar 

  • Draghia R, Caillaud C, Manicom R, Pavirani A, Kahn A, Poenaru L (1995) Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther 2:418–23

    PubMed  CAS  Google Scholar 

  • During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Med 9:1173–1179

    Article  PubMed  CAS  Google Scholar 

  • Frey WH 2nd (1991) Neurologic agents for nasal administration the brain. World Intellectual Property Organization. PCT priority date 5.12.89, WO 91/07947

  • Frey WH 2nd (2002) Bypassing the blood–brain barrier to delivery thereapeutic agents to the brain and spinal cord. Drug Deliv Technol (5):46–49

  • Frey WH 2nd, Liu, J, Chen, X, Thorne, RG, Fawcett, JR, Ala, TA, Rahman, Y-E (1997) Delivery of 125I-NGF to the brain via the olfactory route. Drug Deliv 4:87–92

    CAS  Google Scholar 

  • Gimenez F, Fernandez C, Mabondzo A (2004) Transport of HIV protease inhibitors through the blood–brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr 36:649–58

    PubMed  CAS  Google Scholar 

  • Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE (2000) A novel VIP responsive gene. Activity dependent neuroprotective protein. Ann NY Acad Sci 921:115–118

    Article  PubMed  CAS  Google Scholar 

  • Graff CL, Pollack GM (2003) P-glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20:1225–1230

    Article  PubMed  CAS  Google Scholar 

  • Graff CL, Pollack GM (2005) Functional evidence for P-glycoprotein at the nose–brain barrier. Pharm Res 22:86–93

    Article  PubMed  CAS  Google Scholar 

  • Hallschmid M, Benedict C, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin reduces body fat in men but not in women. Diabetes 53:3024–3029

    PubMed  CAS  Google Scholar 

  • Hallschmid M, Smolnik R, McGregor G, Born J, Fehm HL (2006) Overweight humans are resistant to the weight-reducing effects of melanocortin4–10. J Clin Endocrinol Metab 91:522–525

    Article  PubMed  CAS  Google Scholar 

  • Hanson LR, Martinez PM, Taheri S, Kamsheh L, Mignot E, Frey WH 2nd (2004) Intranasal administration of hypocretin 1 (orexin A) bypasses the blood–brain barrier and targets the brain: a new strategy for the treatment of narcolepsy. Drug Delive Technol 4:65–71

    Google Scholar 

  • Hashizume R, Ozawa T, Gryaznov SM, Santos RA, Lamborn KR, Frey WH 2nd, Deen DF (2006) Intranasal delivery of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. American Association of Neurological Surgeons Abstract: 2006 Apr 24

  • Heseltine PN, Goodkin K, Atkinson JH, Vitello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES (1998) Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 55:41–51

    Article  PubMed  CAS  Google Scholar 

  • Jerusalmi A, Morris-Downes MM, Sheahan BJ, Atkins GJ (2003) Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 8:886

    Article  PubMed  CAS  Google Scholar 

  • Jin K, Xie L, Childs J, Sun Y, Mao XO, Logvinova A, Greenberg DA (2003) Cerebral neurogenesis is induced by intranasal administration of growth factors. Ann Neurol 53:405–409

    Article  PubMed  CAS  Google Scholar 

  • Kandimalla KK, Donovan MD (2005a) Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm Res 22:1121–1128

    Article  PubMed  CAS  Google Scholar 

  • Kandimalla KK, Donovan MD (2005b) Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci 94:613–624

    Article  PubMed  CAS  Google Scholar 

  • Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS (1986). Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233:1089–93

    Article  PubMed  CAS  Google Scholar 

  • Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435(7042):673–676

    Article  PubMed  CAS  Google Scholar 

  • Laing JM, Gober MD, Golembewski EK, Thompson SM, Gyure KA, Yarowsky PJ, Aurelian L (2006) Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol Ther 13(5):870–881

    Article  PubMed  CAS  Google Scholar 

  • Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77:10078–10087

    Article  PubMed  CAS  Google Scholar 

  • Liu XF, Fawcett JR, Hanson LR, Frey WH 2nd (2004) The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 13:16–23

    Article  PubMed  Google Scholar 

  • Panter SS, Coppes VG, Ferrell CM, Chavez JC, Ratan RR, Frey WH 2nd (2004) Intranasal deferoxamine protects against subsequent stroke. Program No. 456.15.2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience

    Google Scholar 

  • Pereira CF, Nottet HLSM (2000) The blood–brain barrier in HIV-associated Dementia. NeuroAids 3(2), online

  • Polianova MT, Ruscetti FW, Pert CB, Tractenberg RE, Leoung G, Strang S, Ruff MR (2003) Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides 24:1093–1098

    Article  PubMed  CAS  Google Scholar 

  • Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27:451–458

    Article  PubMed  CAS  Google Scholar 

  • Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH 2nd (2004) Intranasal administration of interferon beta bypasses the blood–brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151:66–77

    Article  PubMed  CAS  Google Scholar 

  • Ruff MR, Polianova M, Pert CB, Ruscetti FW (2001) Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res 52–63

  • Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB (2003) Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res 1:51–67

    Article  PubMed  CAS  Google Scholar 

  • Schulz C, Paulus K, Lehnert H (2004) Central nervous and metabolic effects of intranasally applied leptin. Endocrinol 145:2696–2701

    Article  CAS  Google Scholar 

  • Shimizu H, Oh-I S, Okada S, Mori M (2005) Inhibition of appetite by nasal leptin administration in rats. Int J Obes 29:858–863

    Article  CAS  Google Scholar 

  • Shingaki T, Sakane T, Yamashita S, Sezaki H, Tokunaga Y, Shibata S (1999) Transnasal delivery of anticancer drugs to the brain tumors: a new strategy for brain tumor chemotherapy. Drug Deliv Syst 14:365–371

    CAS  Google Scholar 

  • Thorne, RG, Frey WH 2nd (2001) Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40:907–946

    Article  PubMed  CAS  Google Scholar 

  • Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481–96

    Article  PubMed  CAS  Google Scholar 

  • Vazeux R, Brousse N, Jarry A, Henin D, Marche C, Vedrenne C, Mikol J, Wolff M, Michon C, Rozenbaum W, Bureau JF, Montagnier L, Brahic M (1987). AIDS subacute encephalitis. Identification of HIV-infected cells. Am J Pathol 126:403–410

    PubMed  CAS  Google Scholar 

  • Wang D, Gao Y, Yun L (2005) Study on brain targeting of raltitrexed following intranasal administration in rats. Cancer Chemother Pharmacol 57:97–104

    Article  PubMed  CAS  Google Scholar 

  • Wang F, Jiang XG, Lu W (2004) Intranasal delivery of methotrexate to the brain in rats bypassing the blood–brain barrier. Drug Deliv Technol 4:48–55

    Google Scholar 

  • Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 83:7089–7093

    Article  PubMed  CAS  Google Scholar 

  • Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ (2005) Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 387:5–10

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant from the NIH to W.H.F. (MH072473).

Author information

Authors and Affiliations

  1. Alzheimer’s Research Center at Regions Hospital, HealthPartners Research Foundation, 640 Jackson Street, Mailstop 11203A, St. Paul, Minnesota, MN, USA

    Leah R. Hanson & William H. Frey II

  2. Department of Pharmaceutics, University of Minnesota, Minneapolis, MN, 55101, USA

    William H. Frey II

Authors
  1. Leah R. Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William H. Frey II
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William H. Frey II.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanson, L.R., Frey, W.H. Strategies for Intranasal Delivery of Therapeutics for the Prevention and Treatment of NeuroAIDS. Jrnl Neuroimmune Pharm 2, 81–86 (2007). https://doi.org/10.1007/s11481-006-9039-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11481-006-9039-x

Key words

Search

Navigation